NASDAQ:ACHL

Achilles Therapeutics plc American Depositary Shares Stock Forecast, Price & News

$12.97

-0.08 (-0.61 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$12.79

Now: $12.97▼

$13.32

50-Day Range N/A

52-Week Range

$12.63

Now: $12.97▼

$18.95

Volume71,328 shs

Average Volume235,016 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ACHL

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.achillestx.com

Phone44 20 8154 4600

Employees153

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A

Market CapN/A

Next Earnings DateN/A

OptionableNot Optionable

Headlines

Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
April 6, 2021 | finance.yahoo.com

UK-based Achilles Therapeutics unveils US$175.5mln IPO at Nasdaq debut
April 1, 2021 | proactiveinvestors.com

Achilles Therapeutics Announces Pricing of Initial Public Offering
April 1, 2021 | finance.yahoo.com

Two Companies Went Public Today. One Climbed, the Other Dropped.
April 1, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

2003rd out of 2,019 stocks

Biotechnology Industry

139th out of 145 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Achilles Therapeutics plc American Depositary Shares.

0.0 Community Rank

Outperform Votes
Achilles Therapeutics plc American Depositary Shares has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Achilles Therapeutics plc American Depositary Shares has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Achilles Therapeutics plc American Depositary Shares and other stocks. Vote “Outperform” if you believe ACHL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACHL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Achilles Therapeutics plc American Depositary Shares does not currently pay a dividend.
Dividend Growth
Achilles Therapeutics plc American Depositary Shares does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Achilles Therapeutics plc American Depositary Shares insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$12.97

-0.08 (-0.61 %)

(As of 04/13/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ACHL News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter.

Achilles Therapeutics plc American Depositary Shares (NASDAQ:ACHL) Frequently Asked Questions

What stocks does MarketBeat like better than Achilles Therapeutics plc American Depositary Shares?

Wall Street analysts have given Achilles Therapeutics plc American Depositary Shares a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Achilles Therapeutics plc American Depositary Shares wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Achilles Therapeutics plc American Depositary Shares' key executives?

Achilles Therapeutics plc American Depositary Shares' management team includes the following people:

Dr. Iraj Ali, CEO & Director (Age 45)
Dr. Karl Peggs M.D., Founder & Chief Medical Officer (Age 54)
Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Founder (Age 58)
Dr. Charles Swanton, Founder (Age 49)
Dr. Sergio A. Quezada Ph.D., Founder & Chief Scientific Officer (Age 46)
Mr. Robert Coutts, Chief Financial Officer (Age 37)
Mr. Daniel Hood, Chief Legal Officer
Julia Wilson, Head of Communications
Mr. Tariq Ahmed, VP of People
Ms. Beverley Carr, Chief Bus. Officer

Who are some of Achilles Therapeutics plc American Depositary Shares' key competitors?

Some companies that are related to Achilles Therapeutics plc American Depositary Shares include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of ACHL's competitors.

When did Achilles Therapeutics plc American Depositary Shares IPO?

(ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.

What is Achilles Therapeutics plc American Depositary Shares' stock symbol?

Achilles Therapeutics plc American Depositary Shares trades on the NASDAQ under the ticker symbol "ACHL."

When does Achilles Therapeutics plc American Depositary Shares' quiet period expire?

Achilles Therapeutics plc American Depositary Shares' quiet period expires on Monday, May 10th. Achilles Therapeutics plc American Depositary Shares had issued 9,750,000 shares in its initial public offering on March 31st. The total size of the offering was $175,500,000 based on an initial share price of $18.00. During Achilles Therapeutics plc American Depositary Shares' quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Achilles Therapeutics plc American Depositary Shares?

Shares of ACHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achilles Therapeutics plc American Depositary Shares' stock price today?

One share of ACHL stock can currently be purchased for approximately $12.97.

How many employees does Achilles Therapeutics plc American Depositary Shares have?

Achilles Therapeutics plc American Depositary Shares employs 153 workers across the globe.

What is Achilles Therapeutics plc American Depositary Shares' official website?

The official website for Achilles Therapeutics plc American Depositary Shares is www.achillestx.com.

How can I contact Achilles Therapeutics plc American Depositary Shares?

The company can be reached via phone at 44 20 8154 4600.

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Achilles Therapeutics plc American Depositary Shares Stock Forecast, Price & News

Adding

Adding

Adding Achilles Therapeutics plc American Depositary Shares